The landscape of dementia prognosis has evolved considerably with the advent of refined biomarkers, which include amyloid PET scans, tau imaging, and blood-based tests which can detect Alzheimer's pathology many years just before signs or symptoms arise. Though these technological innovations represent exceptional progress in comprehension neurodeg